



## Histiocytic Disorders of the Lung: Updates in Diagnosis, Molecular Alterations, and Novel Therapeutics Options

Guest Editor:

**Dr. Sergio Piña-Oviedo**

Department of Pathology, Duke  
University Medical Center,  
Durham, NC 27710, USA

Deadline for manuscript  
submissions:

**30 September 2024**

### Message from the Guest Editor

Although rare, histiocytic disorders may affect the lung in the form of either a primary or secondary disease. These disorders include Langerhans cell histiocytosis; Erdheim–Chester disease; Rosai–Dorfman disease; juvenile xanthogranuloma; crystal-storing histiocytosis; as well as other less well-known entities, such as ALK+ or NTRK+ histiocytosis/histiocytic tumors. Once considered reactive proliferations, several studies published within the last two decades have shown that at least a subset of these disorders are clonal- and/or harbor-specific molecular alterations that may translate into potential therapeutic targets, such as with the detection of recurrent genetic alterations in molecules involved in the activation of the RAS/RAF/MAPK signaling pathway. This Special Issue is dedicated to the study of current and emerging tools in the diagnostic armamentarium of pulmonary histiocytic disorders as well as to novel and promising therapeutic approaches, including the use of molecularly targeted therapies.

For more information, please visit Special Issue [website](#).

